We report here the main MRI findings of a dose escalation phase 1 clinical trial with intravenous administration of theranostic AGuIX nanoparticles, conducted in 15 patients with brain metastases with the objective of evaluating the efficacy of the nanoparticles as contrast agent and radiosensitizer for brain metastases. The nanoparticles were found to enhance four different histological types of brain metastases up to one week after nanoparticle administration. Quantitative measurements of nanoparticle concentration in all types of brain metastases were obtained two hours after administration to patient - and incidentally two hours before the first session of whole brain radiotherapy.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords